Switch theme
Sign up to access all valuation multiples
China Resources Pharmaceutical is the third-largest medical distributor in China by revenue. It is an integrated pharmaceutical company specializing in research and development, manufacturing, medical distribution, and retail pharmacies. As of 2024, the medical distribution business accounts for 82.8% of its total revenue. CR Pharma’s manufacturing business, 18.0% of total revenue, has subsidiaries with a strong presence in traditional Chinese medicine and consumer healthcare.
2007
72.7K+
LTM Revenue $39.5B
LTM EBITDA $2.4B
$7.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CR Pharmaceutical has a last 12-month revenue (LTM) of $39.5B and a last 12-month EBITDA of $2.4B.
In the most recent fiscal year, CR Pharmaceutical achieved revenue of $32.9B and an EBITDA of $2.1B.
CR Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CR Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $39.5B | XXX | $32.9B | XXX | XXX | XXX |
| Gross Profit | $6.1B | XXX | $5.2B | XXX | XXX | XXX |
| Gross Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA | $2.4B | XXX | $2.1B | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| EBIT | $1.9B | XXX | $1.8B | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $542M | XXX | $428M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $6.5B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, CR Pharmaceutical's stock price is HKD 5 (or $1).
CR Pharmaceutical has current market cap of HKD 32.4B (or $4.1B), and EV of HKD 58.9B (or $7.5B).
See CR Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.5B | $4.1B | XXX | XXX | XXX | XXX | $0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, CR Pharmaceutical has market cap of $4.1B and EV of $7.5B.
CR Pharmaceutical's trades at 0.2x EV/Revenue multiple, and 3.6x EV/EBITDA.
Equity research analysts estimate CR Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CR Pharmaceutical has a P/E ratio of 8.3x.
See valuation multiples for CR Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.1B | XXX | $4.1B | XXX | XXX | XXX |
| EV (current) | $7.5B | XXX | $7.5B | XXX | XXX | XXX |
| EV/Revenue | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | 3.5x | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBIT | 4.3x | XXX | 4.3x | XXX | XXX | XXX |
| EV/Gross Profit | 1.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 8.3x | XXX | 9.7x | XXX | XXX | XXX |
| EV/FCF | -14.1x | XXX | 4.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCR Pharmaceutical's last 12 month revenue growth is 8%
CR Pharmaceutical's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $47K for the same period.
CR Pharmaceutical's rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CR Pharmaceutical's rule of X is 25% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CR Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | 14% | XXX | 14% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 25% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $47K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CR Pharmaceutical acquired XXX companies to date.
Last acquisition by CR Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . CR Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CR Pharmaceutical founded? | CR Pharmaceutical was founded in 2007. |
| Where is CR Pharmaceutical headquartered? | CR Pharmaceutical is headquartered in Hong Kong. |
| How many employees does CR Pharmaceutical have? | As of today, CR Pharmaceutical has 72.7K+ employees. |
| Who is the CEO of CR Pharmaceutical? | CR Pharmaceutical's CEO is Mr. Xiaosong Bai. |
| Is CR Pharmaceutical publicy listed? | Yes, CR Pharmaceutical is a public company listed on HKG. |
| What is the stock symbol of CR Pharmaceutical? | CR Pharmaceutical trades under 03320 ticker. |
| When did CR Pharmaceutical go public? | CR Pharmaceutical went public in 2016. |
| Who are competitors of CR Pharmaceutical? | Similar companies to CR Pharmaceutical include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of CR Pharmaceutical? | CR Pharmaceutical's current market cap is $4.1B |
| What is the current revenue of CR Pharmaceutical? | CR Pharmaceutical's last 12 months revenue is $39.5B. |
| What is the current revenue growth of CR Pharmaceutical? | CR Pharmaceutical revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of CR Pharmaceutical? | Current revenue multiple of CR Pharmaceutical is 0.2x. |
| Is CR Pharmaceutical profitable? | Yes, CR Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CR Pharmaceutical? | CR Pharmaceutical's last 12 months EBITDA is $2.4B. |
| What is CR Pharmaceutical's EBITDA margin? | CR Pharmaceutical's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of CR Pharmaceutical? | Current EBITDA multiple of CR Pharmaceutical is 3.5x. |
| What is the current FCF of CR Pharmaceutical? | CR Pharmaceutical's last 12 months FCF is -$579M. |
| What is CR Pharmaceutical's FCF margin? | CR Pharmaceutical's last 12 months FCF margin is -1%. |
| What is the current EV/FCF multiple of CR Pharmaceutical? | Current FCF multiple of CR Pharmaceutical is -14.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
